Inotiv Inc NOTV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NOTV is a good fit for your portfolio.
News
-
INOTIV INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inotiv, Inc. - NOTV
-
INOTIV INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inotiv, Inc. - NOTV
-
Inotiv Reports First Quarter Financial Results for Fiscal 2024 and Provides Business Update
-
Inotiv, Inc. to Report Fiscal 2024 First Quarter Financial Results and Host Conference Call on Wednesday, February 7, 2024
Trading Information
- Previous Close Price
- $4.29
- Day Range
- $3.97–4.35
- 52-Week Range
- $1.61–11.42
- Bid/Ask
- $4.05 / $4.44
- Market Cap
- $104.45 Mil
- Volume/Avg
- 328,347 / 497,773
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.19
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Core
- Total Number of Employees
- 2,055
- Website
- https://www.inotivco.com
Comparables
Valuation
|
Metric
|
NOTV
|
OCEA
|
ACRS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.44 | — | 0.54 |
Price/Sales | 0.19 | — | 2.66 |
Price/Cash Flow | 3.97 | — | — |
Price/Earnings
NOTV
OCEA
ACRS
Financial Strength
|
Metric
|
NOTV
|
OCEA
|
ACRS
|
|---|---|---|---|
Quick Ratio | 1.06 | 0.04 | 3.86 |
Current Ratio | 1.74 | 0.08 | 4.16 |
Interest Coverage | 0.07 | −76.60 | — |
Quick Ratio
NOTV
OCEA
ACRS
Profitability
|
Metric
|
NOTV
|
OCEA
|
ACRS
|
|---|---|---|---|
Return on Assets (Normalized) | −2.71% | −115.11% | −38.26% |
Return on Equity (Normalized) | −8.57% | −205.86% | −50.08% |
Return on Invested Capital (Normalized) | 1.67% | −167.13% | −49.93% |
Return on Assets
NOTV
OCEA
ACRS
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Zpkqhfftf | Kjsk | $209.3 Bil | |
DHR
| Danaher Corp | Jxrlxwrplc | Phtlpc | $182.1 Bil | |
IQV
| IQVIA Holdings Inc | Vlxswdlzd | Bdwbj | $43.4 Bil | |
IDXX
| IDEXX Laboratories Inc | Wdfnwhfgr | Vxzjz | $41.0 Bil | |
A
| Agilent Technologies Inc | Qfwhqqjjn | Zjbs | $40.3 Bil | |
MTD
| Mettler-Toledo International Inc | Rszdcwfn | Ykykjs | $26.4 Bil | |
ICLR
| Icon PLC | Zslhywwd | Tgyml | $24.8 Bil | |
ILMN
| Illumina Inc | Vdczhtkl | Mmhqqf | $19.3 Bil | |
WAT
| Waters Corp | Fxrnffsq | Llm | $18.3 Bil | |
LH
| Laboratory Corp of America Holdings | Glyhxfzg | Dwynztc | $17.5 Bil |